The emerging domain of pediatric pharmacogenetics seeks to optimize medication regimens based on genetic variation influencing drug metabolism in children. Unlike adult populations, pediatric patients present unique physiological development stages affecting enzymatic pathways such as cytochrome P450 enzymes. Understanding gene variants, exemplified by CYP2D6 polymorphisms, informs precise dosing to enhance efficacy and minimize adverse events. Integrating genetic data into clinical settings holds promise for safer, tailored pediatric therapeutics, facilitating transition beyond generalized prescriptions.